TCM 800B

Drug Profile

TCM 800B

Latest Information Update: 20 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TCM Biotech International
  • Developer Industrial Technology Research Institute; TCM Biotech International
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 01 Jan 2015 Preclinical trials in Hepatitis B in Taiwan (unspecified route) before January 2015
  • 01 Jan 2015 Taiwan FDA approves IND application for TCM 800B in Hepatitis B (TCM Biotech International website, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top